"For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care." Current treatments like steroids and immunosuppressants may come ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Enveda Therapeutics Inc. has received U.S. IND clearance and advanced into phase I trials with ENV-294, its naturally derived anti-inflammatory.

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...